Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Neurointerv Surg. 2016 Dec 28;10(1):29–33. doi: 10.1136/neurintsurg-2016-012793

Figure 1.

Figure 1

(A) Blood perfusion measurements as percentage change from baseline for combined groups (black dot), control (red line), 3.12 μg/μL (green line), 6.25 μg/μL (gray line), and 12.5 μg/μL (blue line) at baseline (0–5 min), post-occlusion (5 min after occlusion), and post-IA injection (15 min after IA injection). Combined (N=30), control (n=5), 3.12 μg/μL (n=5), 6.25 μg/μL (n=5), and 12.5 μg/μL (n=5). (B) Infarct volume analysis of control versus GTN doses (3.12, 6.25, 12.5, and 25 μg/μL). (C) Cresyl violet image for control, 3.12 μg/μL, 6.25 μg/μL, 12.5 μg/μL, and 25 μg/μL group (n=10 per group). *p<0.05; **p<0.001. GTN, glyceryl trinitrate.